Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.</li>
<li>In this insight, we examine its key product, GASTROClear's technical and clinical data. We also look at the competitive landscape.</li>
<li>We are of the view that the company's product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.</li>
</ul>


Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.
In this insight, we examine its key product, GASTROClear's technical and clinical data. We also look at the competitive landscape.
We are of the view that the company's product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.


Mirxes Pre-IPO: Early Signs of Commercialization Challenges

Mirxes Holding

Mirxes Pre-IPO: Early Signs of Commercialization Challenges